Pulmonary hypertension risk factors: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 21: | Line 21: | ||
Shown below is a table summarizing the list of drugs associated with PAH. | Shown below is a table summarizing the list of drugs associated with PAH. | ||
{| | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
|- | |- | ||
| | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align=center |Definite risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align=center |Possible risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align=center |Likely risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align=center |Unlikely risk | ||
|- | |||
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | | |||
* [[Aminorex]] <br> | * [[Aminorex]] <br> | ||
* [[Fenfluramine]] <br> | * [[Fenfluramine]] <br> | ||
| Line 30: | Line 31: | ||
* Toxic rapeseed oil <br> | * Toxic rapeseed oil <br> | ||
* [[Benfluorex]] | * [[Benfluorex]] | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | | ||
* [[Cocaine]] <br> | * [[Cocaine]] <br> | ||
* [[Phenylpropanolamine]]<br> | * [[Phenylpropanolamine]]<br> | ||
| Line 37: | Line 38: | ||
* [[Selective serotonin reuptake inhibitor]]s <br> | * [[Selective serotonin reuptake inhibitor]]s <br> | ||
* [[Pergolide]] | * [[Pergolide]] | ||
| | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | | ||
* [[Amphetamine]] <br> | * [[Amphetamine]] <br> | ||
* [[L-tryptophan]] <br> | * [[L-tryptophan]] <br> | ||
* [[Metamphetamine]] | * [[Metamphetamine]] | ||
|* [[Oral contraceptive]] | |style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | | ||
* [[Estrogen]] | * [[Oral contraceptive]] | ||
* [[Estrogen|Estrogen therapy]] | |||
* [[Smoking]] | * [[Smoking]] | ||
|} | |} | ||
Revision as of 20:15, 28 August 2014
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension risk factors On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension risk factors |
|
Risk calculators and risk factors for Pulmonary hypertension risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-in-Chief: Ralph Matar
Overview
BMPR2 mutation, systemic sclerosis, HIV infection, portal hypertension, fenfluramine use, congenital heart disease with shunt, recent acute pulmonary embolism, and sickle cell disease are established risk factors for development of pulmonary arterial hypertension. On the other hand, patients in a hypercoagulable state (such as the presence of lupus anticoagulant, deficiency of protein C, protein S, or antithrombin III, chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy) are at an increased risk for chronic thromboembolic pulmonary hypertension.[1]
Risk Factors
Pulmonary Arterial Hypertension
- BMPR2 gene mutation
- ALK1 gene mutation
- Connective tissue disease
- HIV infection
- Portal hypertension
- Congenital heart disease
- Schistosomiasis
- Chronic hemolytic anemia
- Drugs and toxins
Shown below is a table summarizing the list of drugs associated with PAH.
| Definite risk | Possible risk | Likely risk | Unlikely risk |
|
Pulmonary hypertension due to Left Heart Disease
- Systolic dysfunction
- Diastolic dysfunction
- Left valvular disease
Pulmonary Hypertension due to Lung Diseases and/or Hypoxia
- Alveolar hypoventilation disorders
- Chronic exposure to high altitude
- Chronic obstructive pulmonary disease
- Developmental abnormalities
- Interstitial lung disease
- Pulmonary diseases with mixed restrictive and obstructive pattern
- Sleep related breathing problems
Chronic Thromboembolic Pulmonary Hypertension
PH with Unclear and/or Multifactorial Mechanisms
- Myeloproliferative disease
- Splenectomy
- Sarcoidosis
- Histiocytosis
- Lymphangioleiomyomatosis
- Neurofibromatosis
- Vasculitis
- Glycogen storage disease
- Gaucher disease
- Thyroid disorder
- Obstruction by tumor
- Fibrosing mediastinitis
- Chronic renal failure on dialysis
References
- ↑ McLaughlin, VV.; Archer, SL.; Badesch, DB.; Barst, RJ.; Farber, HW.; Lindner, JR.; Mathier, MA.; McGoon, MD.; Park, MH. (2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association". Circulation. 119 (16): 2250–94. doi:10.1161/CIRCULATIONAHA.109.192230. PMID 19332472. Unknown parameter
|month=ignored (help)